Thomson finalizes Solucient purchase

Share this article:
Thomson is buying the balance of Solucient from media giant VNU, private equity firm Veronis Suhler Stevenson and healthcare provider alliance VHA.

Thomson snapped up part of the informatics business—that focused on provision of services to payors—last February.

Now the Stamford-based firm has completed its acquisition of Solucient by picking up its analytics business directed at providers. Those businesses will be folded into Thomson's Medstat informatics unit.

Headquartered in Evanston, IL, Solucient boasts a staff of 500 and a secondary office in Ann Arbor, MI, where Medstat is based. Carol Diephuis, EVP at Thomson Medstat, said the firm might consider consolidating offices in the future, but for now, the companies are highly complementary.

“When you think about the combination of expertise and the massive market need in this space, there's growth opportunities for employees of both organizations,” she said. “Solucient helps round out our offering with a lot of information services for hospital managers as well as pharmaceutical companies.”

Before the acquisition, Thomson Health & Scientific employed 4,700. The firm has been moving away from medical publishing and more heavily into healthcare informatics since its divestiture of its Medical Economics business to Advanstar in October 2003.

Thomson continues to publish PDR. Other Thomson assets include its MercuryMD and Micromedix informatics businesses, aimed at healthcare providers, the CenterWatch suite of products and PDA program Clinical Xpert.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...